�A new imaging system that allows physicians to examine tissue paper at the cellular level from inside the consistency may now enable them to more effectively diagnose cancer of the gall ducts, according to a new survey in the September 2008 issue of the diary Clinical Gastroenterology and Hepatology. This cancer, medically known as cholangiocarcinoma, is one and only of the most unmanageable to find and treat.
"Accurate diagnosis and staging of malignant neoplastic disease of the bile duct remains a challenge scorn advanced imaging methods and the launching of tissue sampling methods," said lead investigator Alexander Meining of the Technical University of Munich. "Adding this noninvasive tool that allows us to persuasion abnormal bile duct tissue paper while it's still inside the body increases diagnostic accuracy of cancer of the bile duct."
Dr. Meining and his colleagues conducted the 14-patient study to measure the ability of the Cellvizio confocal microscopy system to detect neoplasia (an abnormal growth of cells that toilet be benign, pre-cancer or cancer) in biliary piece of ground tissue by examining tissue at the cellular point during Endoscopic Retrograde Cholangiopancreatography (ERCP), a procedure victimized to name cancer of the bile ducts and pancreas.
They found that Cellvizio predicted neoplasia with a sensitivity of 83%, considerably better than the 50% seen with measure histopathological analysis of biopsied tissue taken from strictures. In increase, Cellvizio predicted neoplasia with an accuracy rate of 86%, which was superscript to the 79% truth rate of standard histopathology.
"We believe Cellvizio also might facilitate the detection of other cancers arising from ductal structures in the pancreas, breast and urogenital area," Dr. Meining added.
The researchers also reported that Cellvizio images captured with the dye fluorescein enabled them to better differentiate 'tween patients with bile duct cancer and those without it by allowing them to see abnormal blood vessels present only in patients with cancer.
The specially intentional Cellvizio CholangioFlex Miniprobe enables the Cellvizio System to be secondhand during ERCP procedures and debuted earlier this class at Digestive Disease Week 2008 in May.
Cellvizio is the first and only confocal microscopy system that is compatible with most endoscopes including cholangioscopes and advanced endoscopic modalities. Cellvizio has 510(k) clearance from the Food & Drug Administration and the European CE-Mark for use in the gastrointestinal and pneumonic tracts. Over 1,500 Cellvizio procedures have been completed to date.
About Cholangiocarcinoma
Cholangiocarcinoma is a cancer of the bile ducts, which drain bile from the liver into the small gut. With an annual relative incidence rate of one to two cases per one C,000 in the Western world, this disease has been steadily increasing o'er the past times several decades. Risk factors include inflammation of the bile ducts and liver malfunctions. Symptoms include icterus, weight passing and generalised itching. This disease is diagnosed through and through a combination of blood tests, mental imagery, endoscopy and sometimes surgical exploration. To date, surgery is the only potentially curative handling.
About Cellvizio
Cellvizio Inc. leads the ontogenesis in vivo cellular mental imagery market enabling physicians to visualize, diagnose and treat pathologies that can not be seen using other imaging techniques. The Cellvizio� system provides microscopic visualisation of mucosal tissue and improves clinical outcomes by increasing the diagnostic pay of existent endoscopic procedures. Cellvizio Inc. is currently focused on the gastroenterology and pulmonology markets. The company plans to expand into other markets and diseases indications in the future and also has a statistical distribution agreement with Leica Microsystems to sell products for the Small Animal Imaging market in Europe, the U.S. and Japan. Cellvizio Inc. Is a Mauna Kea Technologies Company.
For more information about Cellvizio, go to: http://www.cellvizio.com.
Cellvizio
More information
